Should clinicians follow the K/DOQI guidelines for treating hyperphosphatemia with sevelamer?

Nature Clinical Practice Nephrology

Volumn 3, Issue 8, 2007, Pages 418-419

  Komaba, Hirotaka ^a   Fukagawa, Masafumi ^a  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Clinical practice guidelines; Cost; Hemodialysis; Hyperphosphatemia; Sevelamer

Indexed keywords

CALCIUM; CALCIUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; SEVELAMER;

AGED; ALGORITHM; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DOSE CALCULATION; DRUG COST; EVIDENCE BASED PRACTICE; FEMALE; HEMODIALYSIS; HORMONE BLOOD LEVEL; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 34547215211     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0536     Document Type: Note

References (7)

1. Chertow GM et al. (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245-252
2. Block GA et al. (2005) Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68: 1815-1824
3. National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 (Suppl 3): S1-S201
4. Manns B et al. (2004) A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int 66: 1239-1247
5. Block GA et al. (2007) Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71: 438-441
6. Suki W et al. (2005) A prospective randomized trial assessing the impact on outcomes of sevelamer in dialysis patients [abstract]. J Am Soc Nephrol 16: 281A
7. Garside R et al. (2007) The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective. Nephrol Dial Transplant 22: 1428-1436